Abionic

Coming – December 3

Detecting Sepsis Before It's Too Late

Date and Time

December 3

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

A Seven-Minute Test. Up to 72 Hours of Early Warning. A New Opportunity in Medical Diagnostics.

Sepsis affects approximately 49 million people worldwide annually and claims 11 million lives. Early detection remains one of medicine’s greatest challenges, and Abionic, a Swiss medical technology company, has developed a breakthrough diagnostic platform designed to address this critical need.

Join us for a Fireside Chat with Abionic CEO Patrick Pestalozzi to explore how the company’s proprietary nanofluidic technology could transform early sepsis detection and create opportunities across the $5.5 billion market it has identified.

Key highlights include:
  • 72-Hour Early Warning: Abionic’s proprietary PSP biomarker may identify sepsis risk 48 to 72 hours before clinical symptoms appear.
  • Seven-Minute Results: The abioSCOPE® platform delivers quantitative results from a single drop of blood, directly at the point of care.
  • Regulatory Progress: FDA 510(k) clearance for the platform, CE marking, and regulatory coverage in more than 30 countries.
  • Commercial Momentum: Hospital pilot programs underway in Germany and the UK, with a strategy for expanding into the U.S. market.
  • Scalable Manufacturing: An ISO-certified Swiss production facility capable of producing up to two million test cartridges annually.
  • Platform Potential: Proprietary technology designed to support multiple diagnostic applications beyond sepsis.

With its technology developed, clinical evidence growing, and commercialization efforts advancing, Abionic is approaching a potentially significant inflection point.

Join us to discuss the company’s progress, upcoming clinical and regulatory milestones, U.S. commercialization strategy, and vision for the future of rapid diagnostics.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.